Sean Galligan, MD
Interventional Cardiology · Staten Island, NYNPI 1982995692
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 404 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in NY, where the typical reported total is $8,047.
Across 404 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Johnson & Johnson$1K
- Amgen$1K
- Novartis$950
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$817
- Pfizer$436
- plus $2K from 29 others
Across 3 payments — averaging $3346.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$10K
What the payments were for
- Food & beverage$8,04399%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 76 | $1,298 |
| Johnson & Johnson | 61 | $1,171 |
| Amgen | 54 | $1,102 |
| Novartis | 52 | $950 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 33 | $817 |
| Pfizer | 21 | $436 |
| Merck | 20 | $341 |
| Medtronic(2 entities) | 6 | $306 |
| Boehringer Ingelheim | 10 | $218 |
| Alnylam Pharmaceuticals Inc. | 9 | $192 |
| Sanofi-aventis U.S. LLC | 6 | $143 |
| E.r. Squibb & Sons, L.L.C. | 9 | $136 |
| Abiomed | 5 | $135 |
| Actelion Pharmaceuticals US, Inc. | 2 | $123 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $108 |
| Abbott | 3 | $89 |
| Esperion Therapeutics, Inc. | 4 | $57 |
| Amarin Pharma, Inc. | 3 | $53 |
| Baxter Healthcare | 1 | $46 |
| Bayer | 2 | $45 |
| Novo Nordisk | 2 | $43 |
| Lexicon Pharmaceuticals, Inc. | 2 | $43 |
| Boston Scientific | 2 | $41 |
| Philips North America LLC | 2 | $41 |
| Cardiovascular Systems Inc. | 2 | $27 |
| AbbVie | 2 | $27 |
| CSL Behring | 1 | $24 |
| Shionogi Inc | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $20 |
| TELA Bio, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$265
- CoreValve Evolut$209
- VYNDAQEL$125
- Repatha$125
- AIMOVIG$123
How this compares
$8,142 in reported general payments places this provider in the 50th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 145 | $141,838 |
| EntrestoSacubitril/Valsartan | 103 | $108,491 |
| XareltoRivaroxaban | 72 | $60,411 |
| JardianceEmpagliflozin | 36 | $35,118 |
| FarxigaDapagliflozin Propanediol | 22 | $25,252 |
| Repatha SureclickEvolocumab | 28 | $15,026 |
| Metoprolol Succinate | 316 | $4,154 |
| Atorvastatin Calcium | 303 | $2,668 |
| Amlodipine Besylate | 185 | $1,430 |
| Losartan Potassium | 105 | $1,362 |
| Nifedipine ErNifedipine | 46 | $1,135 |
| Rosuvastatin Calcium | 74 | $823 |
| ClopidogrelClopidogrel Bisulfate | 109 | $729 |
| Furosemide | 129 | $476 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 52 | $463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $436 | $141,838145 claims |
| NovartisEntresto | $950 | $108,491103 claims |
| Johnson & JohnsonXarelto | $1,171 | $60,41172 claims |
| Boehringer IngelheimJardiance | $218 | $35,11836 claims |
| AstraZenecaFarxiga | $1,298 | $25,25222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Staten Island
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- David CohenRoslyn$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.